93 related articles for article (PubMed ID: 12684403)
1. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.
Welt S; Ritter G; Williams C; Cohen LS; Jungbluth A; Richards EA; Old LJ; Kemeny NE
Clin Cancer Res; 2003 Apr; 9(4):1347-53. PubMed ID: 12684403
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of anticolon cancer humanized antibody A33.
Welt S; Ritter G; Williams C; Cohen LS; John M; Jungbluth A; Richards EA; Old LJ; Kemeny NE
Clin Cancer Res; 2003 Apr; 9(4):1338-46. PubMed ID: 12684402
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.
Scott AM; Lee FT; Jones R; Hopkins W; MacGregor D; Cebon JS; Hannah A; Chong G; U P; Papenfuss A; Rigopoulos A; Sturrock S; Murphy R; Wirth V; Murone C; Smyth FE; Knight S; Welt S; Ritter G; Richards E; Nice EC; Burgess AW; Old LJ
Clin Cancer Res; 2005 Jul; 11(13):4810-7. PubMed ID: 16000578
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
Chong G; Lee FT; Hopkins W; Tebbutt N; Cebon JS; Mountain AJ; Chappell B; Papenfuss A; Schleyer P; U P; Murphy R; Wirth V; Smyth FE; Potasz N; Poon A; Davis ID; Saunder T; O'keefe GJ; Burgess AW; Hoffman EW; Old LJ; Scott AM
Clin Cancer Res; 2005 Jul; 11(13):4818-26. PubMed ID: 16000579
[TBL] [Abstract][Full Text] [Related]
5. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
6. Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine.
Herbertson RA; Tebbutt NC; Lee FT; Gill S; Chappell B; Cavicchiolo T; Saunder T; O'Keefe GJ; Poon A; Lee ST; Murphy R; Hopkins W; Scott FE; Scott AM
J Nucl Med; 2014 Apr; 55(4):534-9. PubMed ID: 24556590
[TBL] [Abstract][Full Text] [Related]
7. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
[TBL] [Abstract][Full Text] [Related]
9. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
Wong JY; Chu DZ; Williams LE; Yamauchi DM; Ikle DN; Kwok CS; Liu A; Wilczynski S; Colcher D; Yazaki PJ; Shively JE; Wu AM; Raubitschek AA
Clin Cancer Res; 2004 Aug; 10(15):5014-21. PubMed ID: 15297402
[TBL] [Abstract][Full Text] [Related]
10. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
[TBL] [Abstract][Full Text] [Related]
11. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of the chimeric monoclonal antibody (c30.6) in patients with metastatic colorectal cancer.
Ward RL; Packham D; Smythe AM; Murray J; Anderson-Stewart P; Kitchen N; Muirhead R; Phillips P; Gray P; Bigg-Wither G; Prabakaran K; Freund J; Fullham M; Rule M; Dalley D; Meagher A; Hawkins NJ; Smith GM
Clin Cancer Res; 2000 Dec; 6(12):4674-83. PubMed ID: 11156219
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
[TBL] [Abstract][Full Text] [Related]
15. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
Van Hazel G; Blackwell A; Anderson J; Price D; Moroz P; Bower G; Cardaci G; Gray B
J Surg Oncol; 2004 Nov; 88(2):78-85. PubMed ID: 15499601
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
[TBL] [Abstract][Full Text] [Related]
17. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
18. Influence of size, surface, cell line, and kinetic properties on the specific binding of A33 antigen-targeted multilayered particles and capsules to colorectal cancer cells.
Cortez C; Tomaskovic-Crook E; Johnston AP; Scott AM; Nice EC; Heath JK; Caruso F
ACS Nano; 2007 Sep; 1(2):93-102. PubMed ID: 19206525
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
Al-Batran SE; Atmaca A; Schleyer E; Pauligk C; Hosius C; Ehninger G; Jäger E
Cancer; 2007 May; 109(9):1897-904. PubMed ID: 17377918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
